Neurocrine Biosciences Inc (NBIX)
Gross profit margin
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit (ttm) | US$ in thousands | 1,312,300 | 1,254,200 | 1,156,700 | 1,049,800 | 953,900 | 887,400 | 799,400 | 699,700 | 635,200 | 574,500 | 510,800 | 528,800 | 524,400 | 613,200 | 617,400 | 676,200 | 689,000 | 685,110 | 679,877 | 577,883 |
| Revenue (ttm) | US$ in thousands | 2,355,300 | 2,241,400 | 2,117,000 | 1,978,200 | 1,882,900 | 1,779,300 | 1,668,300 | 1,522,900 | 1,411,600 | 1,306,100 | 1,208,800 | 1,185,500 | 1,107,700 | 1,050,200 | 1,010,800 | 1,022,200 | 1,020,900 | 1,017,010 | 981,066 | 862,604 |
| Gross profit margin | 55.72% | 55.96% | 54.64% | 53.07% | 50.66% | 49.87% | 47.92% | 45.95% | 45.00% | 43.99% | 42.26% | 44.61% | 47.34% | 58.39% | 61.08% | 66.15% | 67.49% | 67.37% | 69.30% | 66.99% |
December 31, 2024 calculation
Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $1,312,300K ÷ $2,355,300K
= 55.72%
Over the period from March 31, 2020, to December 31, 2024, Neurocrine Biosciences Inc's gross profit margin has exhibited fluctuations. The margin started at a relatively high level of 66.99% in March 2020 and increased further to 69.30% by June 2020. However, there was a slight decrease to 67.37% by September 2020 and then remained relatively stable around the mid to high 60% range until December 2020.
From March 2021 to December 2021, the gross profit margin showed a decreasing trend, dropping from 66.15% to 47.34%. This significant decline over the year indicates a potential impact on the company's profitability or cost structure.
The trend continued into 2022, with the margin decreasing to 42.26% by June and then slightly recovering to 45.00% by December 2022. However, in 2023, there was a gradual improvement in the gross profit margin, increasing to 50.66% by December 2023, indicating potential operational efficiencies or changes in the product mix.
The positive trend continued into 2024, where the gross profit margin further improved to 55.72% by December 2024. Overall, while there were periods of fluctuation and decline in the gross profit margin, Neurocrine Biosciences Inc managed to show improvement and stabilization in its profitability over the analyzed period.
Peer comparison
Dec 31, 2024